{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Brain+Tumors&page=3",
    "query": {
      "condition": "Malignant Brain Tumors",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 564,
    "total_pages": 57,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Brain+Tumors&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Brain+Tumors&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T22:02:48.352Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00114309",
      "title": "131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme",
        "GBM",
        "Anaplastic Astrocytoma",
        "Oligo-Astrocytoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "131-I-TM-601",
          "type": "DRUG"
        },
        {
          "name": "131I-TM601",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransMolecular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2004-11",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2009-04-03",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00114309"
    },
    {
      "nct_id": "NCT00030498",
      "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Mixed Glioma",
        "Adult Myxopapillary Ependymoma",
        "Adult Oligodendroglioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Primary Hepatocellular Carcinoma",
        "Adult Subependymoma",
        "Advanced Adult Primary Liver Cancer",
        "Advanced Malignant Mesothelioma",
        "Male Breast Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adult Brain Tumor",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Bladder Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Esophageal Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage II Esophageal Cancer",
        "Stage II Pancreatic Cancer",
        "Stage III Esophageal Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Anal Cancer",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Bladder Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esophageal Cancer",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2001-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030498"
    },
    {
      "nct_id": "NCT01144247",
      "title": "Cellular Immunotherapy Study for Brain Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gliomas",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Mixed Glioma",
        "Glioblastoma Multiforme",
        "Malignant Meningioma"
      ],
      "interventions": [
        {
          "name": "alloreactive CTL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-07",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-05-27",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144247"
    },
    {
      "nct_id": "NCT03175432",
      "title": "Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAF V600 Wild Type",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Intracranial Melanoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-06-15",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175432"
    },
    {
      "nct_id": "NCT02095132",
      "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Embryonal Tumor With Rhabdoid Features",
        "Central Nervous System Embryonal Tumor, Not Otherwise Specified",
        "Central Nervous System Ganglioneuroblastoma",
        "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered",
        "Pineoblastoma",
        "Primary Central Nervous System Neoplasm",
        "Recurrent Childhood Central Nervous System Embryonal Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 76,
      "start_date": "2014-03-28",
      "completion_date": "2023-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-26",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02095132"
    },
    {
      "nct_id": "NCT01989052",
      "title": "Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma (WHO Grade III or IV)"
      ],
      "interventions": [
        {
          "name": "CTO",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2014-05",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01989052"
    },
    {
      "nct_id": "NCT02667587",
      "title": "An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Neoplasms"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2016-05-09",
      "completion_date": "2024-04-09",
      "has_results": true,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02667587"
    },
    {
      "nct_id": "NCT00005952",
      "title": "Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2000-08",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005952"
    },
    {
      "nct_id": "NCT00002965",
      "title": "Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "Recombinant Interferon Alfa (INF alpha)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "1997-01",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002965"
    },
    {
      "nct_id": "NCT03278249",
      "title": "Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Modified Atkins Ketogenic Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-10-12",
      "completion_date": "2022-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-06T22:02:48.352Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03278249"
    }
  ]
}